Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset.

Int J Infect Dis

Université Paris Cité, METHODS Team, CRESS, INSERM, INRA, Paris, France; Assistance Publique-Hôpitaux de Paris, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Paris, France. Electronic address:

Published: August 2023

Objectives: We aimed to identify trajectories of the evolution of post-COVID-19 condition, up to 2 years after symptom onset.

Methods: The ComPaRe long COVID e-cohort is a prospective cohort of patients with symptoms lasting at least 2 months after SARS-CoV2 infection. We used trajectory modeling to identify different trajectories in the evolution of post-COVID-19 condition, based on symptoms collected every 60 days using the long COVID Symptom Tool.

Results: A total of 2197 patients were enrolled in the cohort between December 2020 and July 2022 when the Omicron variant was not dominant. Three trajectories of the evolution of post-COVID-19 condition were identified: "high persistent symptoms" (4%), "rapidly decreasing symptoms" (5%), and "slowly decreasing symptoms" (91%). Participants with highly persistent symptoms were older and more likely to report a history of systemic diseases. They often reported tachycardia, bradycardia, palpitations, and arrhythmia. Participants with rapidly decreasing symptoms were younger and more likely to report a confirmed infection. They often reported diarrhea and back pain. Participants with slowly decreasing symptoms were more likely to have a history of functional diseases.

Conclusion: Most patients with post-COVID-19 condition improve slowly over time, while 5% have rapid improvement in the 2 years after symptom onset and 4% have a persistent condition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176960PMC
http://dx.doi.org/10.1016/j.ijid.2023.05.007DOI Listing

Publication Analysis

Top Keywords

post-covid-19 condition
20
trajectories evolution
16
evolution post-covid-19
16
condition years
8
identify trajectories
8
years symptom
8
long covid
8
decreasing symptoms"
8
decreasing symptoms
8
condition
6

Similar Publications

Background/objectives: Millions of individuals worldwide continue to experience symptoms following SARS-CoV-2 infection. This study aimed to assess the prevalence and phenotype of multi-system symptoms attributed to Long COVID-including fatigue, pain, cognitive-emotional disturbances, headache, cardiopulmonary issues, and alterations in taste and smell-that have persisted for at least two years after acute infection, which we define as "persistent Long COVID". Additionally, the study aimed to identify clinical features and blood biomarkers associated with persistent Long COVID symptoms.

View Article and Find Full Text PDF

Special Issue: "Post-COVID-19 Syndrome".

Viruses

December 2024

Institute of Transplantation Diagnostics and Cell Therapy, Division of Hemostasis, Hemotherapy, and Transfusion Medicine, Blood and Hemophilia Comprehensive Care Center, Heinrich Heine University Medical Center, D-40225 Düsseldorf, Germany.

On 30 January 2020, the World Health Organization declared COVID-19 a Public Health Emergency of International Concern (PHEIC)-the highest WHO warning level [...

View Article and Find Full Text PDF

Introduction: COVID-19 vaccinations reduce the severity and number of symptoms for acute SARS-CoV-2 infections and may reduce the risk of developing Long COVID, also known as post-acute sequelae of SARS-CoV-2 (PASC). Limited and heterogenous data exist on how these vaccinations received after COVID-19 infection might impact the symptoms and trajectory of PASC, once persistent symptoms have developed.

Methods: We investigated the association of post-COVID-19 vaccination with any SARS-CoV-2 vaccine(s) on PASC symptoms in two independent cohorts: a retrospective chart review of self-reported data from patients ( = 128) with PASC seen in the Stanford PASC Clinic between May 2021 and May 2022 and a 2023 multinational survey assessment of individuals with PASC ( = 484).

View Article and Find Full Text PDF

The Post-Acute COVID-19-Vaccination Syndrome in the Light of Pharmacovigilance.

Vaccines (Basel)

December 2024

Central Institute of Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, Heinrich Heine University, University Hospital, 40255 Düsseldorf, Germany.

Clinical studies show that SARS-CoV-2 vaccination sometimes entails a severe and disabling chronic syndrome termed post-acute-COVID-19-vaccination syndrome (PACVS). PACVS shares similarities with long COVID. Today, PACVS is still not officially recognised as a disease.

View Article and Find Full Text PDF

Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.

Pathogens

December 2024

Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Japan.

Antibody-dependent enhancement (ADE) is a phenomenon in which antibodies enhance subsequent viral infections rather than preventing them. Sub-optimal levels of neutralizing antibodies in individuals infected with dengue virus are known to be associated with severe disease upon reinfection with a different dengue virus serotype. For Severe Acute Respiratory Syndrome Coronavirus type-2 infection, three types of ADE have been proposed: (1) Fc receptor-dependent ADE of infection in cells expressing Fc receptors, such as macrophages by anti-spike antibodies, (2) Fc receptor-independent ADE of infection in epithelial cells by anti-spike antibodies, and (3) Fc receptor-dependent ADE of cytokine production in cells expressing Fc receptors, such as macrophages by anti-nucleocapsid antibodies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!